Skip to main content

China Biologic Products Holdings, Inc. (CBPO)

Apr 21, 2021 - CBPO was delisted (reason: taken private)
120.02
+0.03 (0.03%)
After-hours:
119.99
1.98 (1.68%)
At close:
Market Cap4.55B
Revenue (ttm)524.37M
Net Income (ttm)152.29M
Shares Out38.58M
EPS (ttm)3.82
PE Ratio31.41
Forward PE22.32
Dividendn/a
Ex-Dividend Daten/a
Volume390,921
Open118.01
Previous Close118.01
Day's Range117.27 - 120.09
52-Week Range99.74 - 120.09
Beta0.42
AnalystsHold
Price Target111.00 (-7.5%)
Est. Earnings DateMay 20, 2021

About CBPO

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also...

IndustryBiotechnology
CEOJoseph Chow
CountryChina
Stock ExchangeNASDAQ
Ticker SymbolCBPO
Full Company Profile

Financial Performance

In 2020, CBPO's revenue was $524.37 million, an increase of 4.09% compared to the previous year's $503.74 million. Earnings were $152.29 million, an increase of 9.71%.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CBPO stock is "Hold." The 12-month stock price forecast is 111.00, which is a decrease of -7.49% from the latest price.

Price Target
$111.00
(-7.49% downside)
Analyst Consensus: Hold

News

China Biologic Announces Completion of Going Private Transaction

BEIJING, April 20, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in Chi...

5 months ago - PRNewsWire

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020

BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in Chi...

5 months ago - PRNewsWire

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2020 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

China Biologic Products to Report Third Quarter 2020 Financial Results

BEIJING, Nov. 13, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in Chi...

10 months ago - PRNewsWire

7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

11 months ago - InvestorPlace

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2020 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

5 Health Care Stocks Boosting Earnings

The following companies have grown their earnings per share over a five-year period.

Other symbols:BIIBGRFSHCAUHS
1 year ago - GuruFocus

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q1 2020 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q4 2019 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

7 Ideal Mid-Cap Stocks for a Diverse Portfolio

These stocks slot into any portfolio and will pack a special punch.

Other symbols:CGKGCMANTVIPS
1 year ago - InvestorPlace

7 Exciting Biotech Stocks to Buy Now

Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.

Other symbols:ACADARWRGLPGNTRAZLAB
1 year ago - InvestorPlace

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2019 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Go-Private Offer For China Biologic Products: It Is Undervalued

As of September 18, 2019, the company received a non-binding proposal to be acquired for $120/share.

2 years ago - Seeking Alpha

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2019 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

5 Undervalued Stocks Growing Book Value

According to the GuruFocus All-In-One Screener, the following companies have grown their book value per share over the past decade.

Other symbols:DFSMGAUHAL
2 years ago - GuruFocus

China Biologic Products Holdings, Inc. (CBPO) Management on Q1 2019 Results - Earnings Call Transcript

China Biologic Products Holdings, Inc. (CBPO) Management on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

China Biologic Products (CBPO) Tops Q1 Earnings and Revenue Estimates

China Biologic Products (CBPO) delivered earnings and revenue surprises of 12.12% and 8.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

Earnings Preview: China Biologic Products (CBPO) Q1 Earnings Expected to Decline

China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

Analysts Estimate China Biologic Products (CBPO) to Report a Decline in Earnings: What to Look Out for

China Biologic Products (CBPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

The fastest growing fast-casual franchise as restaurant spending surges

Jersey Mike's CEO Peter Cancro discusses his company's expansion as restaurant spending in the U.S. has surged in the last three months, to the most on record.

Other symbols:SBUX
3 years ago - CNBC Television